Grifols (GRFS) Debt Ratio (2009 - 2025)

Grifols' (GRFS) quarterly Debt Ratio came in at 0.46 in Q4 2025, up 4.01% YoY from 0.44 in Q4 2024, and up 4.01% on a QoQ basis from 0.44 in Q4 2024.

Grifols (GRFS) Debt Ratio (2009 - 2025) Analysis & Trends

Grifols (GRFS) has 17 years of Debt Ratio data on file, last reported at 0.46 in Q4 2025.

Quarterly Debt Ratio rose 4.01% year-over-year to 0.46 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.46 (up 4.01% YoY) and the FY2025 annual result came in at 0.46, down 99.63% from the prior year.
Debt Ratio rose to 0.46 in Q4 2025, from 0.44 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.53 in Q4 2023 to a low of 0.16 in Q4 2021.
A 5-year average of 0.41 and a median of 0.46 in 2025 frame the typical range for Debt Ratio.
Annual changes were most pronounced in 2021 — Debt Ratio tumbled 63.18% — and 2022, when it jumped 196.85%.
Tracing GRFS's Debt Ratio over 5 years: stood at 0.16 in 2021, then jumped by 196.85% to 0.48 in 2022, then climbed by 9.76% to 0.53 in 2023, then declined by 15.82% to 0.44 in 2024, then climbed by 4.01% to 0.46 in 2025.
The last three Debt Ratio figures came in at 0.46 (Q4 2025), 0.44 (Q4 2024), and 0.53 (Q4 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Johnson & Johnson	653.66 Bn	632.90 Bn	17.26 Bn	0.24
2	AbbVie	469.59 Bn	463.02 Bn	12.70 Bn	0.52
3	Merck	375.61 Bn	368.47 Bn	12.21 Bn	0.42
4	Novartis Ag	302.64 Bn	294.95 Bn	11.24 Bn	0.08
5	Astrazeneca	257.53 Bn	252.63 Bn	12.86 Bn	0.25
6	Amgen	236.78 Bn	222.79 Bn	7.24 Bn	0.66
7	Gilead Sciences	183.22 Bn	180.04 Bn	6.22 Bn	0.58
8	Pfizer	160.17 Bn	148.47 Bn	10.94 Bn	0.31
9	Gsk	105.95 Bn	101.79 Bn	8.24 Bn	-0.31
10	Grifols	5.46 Bn	4.46 Bn	-	0.46

Download Data